Terence Rabbitts

Biography

 Terence worked in Cambridge from 1973-2006 in the MRC Laboratory of Molecular Biology where he was head of the Division of Protein & Nucleic Acid Chemistry until 2002. He moved to become Director of the Leeds Institute of Molecular Medicine (from 2006 to 2010). He is a Member of the European Molecular Biology Organization (EMBO); a Fellow of the Royal Society (FRS); and a Founder Fellow of the Academy of Medical Sciences (FMedSci). His scientific work includes pioneering the method of cDNA cloning, mapping human antibody genes, methods for chimaeric antibody production and single domains for blocking protein interactions inside cells. He defined the linkage of antibody and T cell receptor genes with cancer-specific chromosomal translocations, identified new families of oncogenes (such as the LMO2 and HOX11 families) and identified a first gene fusion in a solid tumor (FUS-CHOP). He developed the first gene fusion knock-in and also methods for creating chromosomal translocations de novo. He has considerable corporate biotechnology experience as chairman of the SAB of Cambridge Antibody Technology and Quadrant Healthcare until their respective IPOs; and a member the Domantis SAB until the company’s acquisition by GSK. He is currently Chairman of the SAB of Kymab and is a member of the SAB of Oryzon Genomics and of DiThera.

Research Interest

 Research interest on Biology